TNL Mediagene Ordinary Shares (TNMG)vsJohn Wiley & Sons B (WLYB)
TNMG
TNL Mediagene Ordinary Shares
$2.00
+1.88%
COMMUNICATION SERVICES · Cap: $81.09M
WLYB
John Wiley & Sons B
$36.99
0.00%
COMMUNICATION SERVICES · Cap: $1.90B
Smart Verdict
WallStSmart Research — data-driven comparison
John Wiley & Sons B generates 3264% more annual revenue ($1.67B vs $49.67M). WLYB leads profitability with a 9.2% profit margin vs -1.7%. WLYB earns a higher WallStSmart Score of 52/100 (C-).
TNMG
Avoid27
out of 100
Grade: F
WLYB
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for TNMG.
Margin of Safety
+62.2%
Fair Value
$81.22
Current Price
$36.99
$44.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 130.0% year-over-year
Every $100 of equity generates 22 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -1.6% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : TNMG
The strongest argument for TNMG centers on Price/Book.
Bull Case : WLYB
The strongest argument for WLYB centers on Revenue Growth, Return on Equity, P/E Ratio. Revenue growth of 130.0% demonstrates continued momentum.
Bear Case : TNMG
The primary concerns for TNMG are EPS Growth, Market Cap, Return on Equity.
Bear Case : WLYB
The primary concerns for WLYB are Altman Z-Score, Market Cap, Debt/Equity.
Key Dynamics to Monitor
TNMG profiles as a turnaround stock while WLYB is a hypergrowth play — different risk/reward profiles.
TNMG carries more volatility with a beta of 1.24 — expect wider price swings.
WLYB is growing revenue faster at 130.0% — sustainability is the question.
WLYB generates stronger free cash flow (167M), providing more financial flexibility.
Bottom Line
WLYB scores higher overall (52/100 vs 27/100) and 130.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
TNL Mediagene Ordinary Shares
COMMUNICATION SERVICES · PUBLISHING · USA
TNL Mediagene Ordinary Shares is a cutting-edge biopharmaceutical company dedicated to developing and commercializing innovative medical therapies aimed at addressing significant unmet health needs, with a focus on oncology and autoimmune disorders. By employing advanced technologies and fostering strong strategic partnerships, the company is strategically positioned for robust growth and long-term value creation. TNL Mediagene’s unwavering commitment to scientific innovation and research-driven approaches highlights its mission to improve patient outcomes and broaden the therapeutic landscape within the biopharmaceutical sector.
Visit Website →John Wiley & Sons B
COMMUNICATION SERVICES · PUBLISHING · USA
John Wiley & Sons, Inc. (WLYB) is a leading global information services company dedicated to advancing the professional and academic success of individuals and institutions. With a diverse portfolio that includes scholarly publishing, professional development resources, and assessment services, Wiley effectively meets the evolving needs of its academic and corporate clientele. The company is at the forefront of innovation in learning, utilizing cutting-edge technologies to enhance accessibility and engagement in education while embracing digital transformation strategies. By focusing on sustainable growth and delivering value to shareholders, Wiley solidifies its position as a key player in the information services industry.
Visit Website →Compare with Other PUBLISHING Stocks
Want to dig deeper into these stocks?